Summary
Definition
History and exam
Key diagnostic factors
- weight loss
- failure to thrive
- vomiting
- hypotension
- atypical genitalia
- hyperpigmentation
Other diagnostic factors
- short stature
- precocious puberty
- irregular menses
- infertility
- male-pattern baldness (females)
- polycystic ovaries
- hirsutism
- acne
Diagnostic investigations
1st investigations to order
- serum 17-hydroxyprogesterone (17-OHP)
- adrenocorticotrophic hormone (ACTH) stimulation test
- serum cortisol
- serum chemistry
- genetic analysis
- karyotype or fluorescence in situ hybridisation (FISH) for X and Y chromosome detection
Investigations to consider
- measurement of additional steroids
- plasma renin activity/plasma renin measurement
- pelvic and adrenal ultrasound
Treatment algorithm
Contributors
Authors
Maria Vogiatzi, MD
Professor of Pediatrics
Division of Endocrinology and Diabetes
Children’s Hospital of Philadelphia
Philadelphia
PA
Disclosures
MV is a consultant for Spruce Bioscience, Crinetics and Eton Pharmaceuticals and receives research support from Neurocrine Bioscience, Spruce Bioscience, Adrenas Therapeutics and Crinetics Pharmaceuticals lnc.
Marissa J Kilberg, MD, MSEd
Assistant Professor of Pediatrics
Division of Endocrinology and Diabetes
Children’s Hospital of Philadelphia
Philadelphia
PA
Disclosures
MK has received consulting fees from Verily, Inc. related to type 1 diabetes. MK receives salary and travel support from the Cystic Fibrosis Foundation as part of the EnVisionIII cohort. MK participates in industry sponsored research but is not the direct recipient of these grants and receives no salary support or travel support from this.
Acknowledgements
The contributors would like to gratefully acknowledge Dr Mabel Yau, Dr Ahmed Kattab, Dr Saroj Nimkarn, Dr Karen Lin-Su, Dr Oksana Lekarev, Dr Maria New, Dr Jessica Kaltman and Dr Adnan Qamar, previous contributors to this topic. MY, AK, SN, JK and AQ declare that they no competing interests. KLS is medical director of the CARES Foundation and an author of several references cited in this topic. OL is on the Medical Advisory Board of the CARES Foundation. MN is an author of several references cited in this topic.
Peer reviewers
Richard Auchus, MD, PhD
Professor of Internal Medicine
Division of Metabolism, Endocrinology and Diabetes
University of Michigan
Ann Arbor
MI
Disclosures
RA contributed to the Endocrine Society CPG on CAH and has been on the board of directors for the past 3 years. He has conducted CAH-related contracted clinical trials and has consulted for Janssen Pharmaceuticals, Millendo Therapeutics, Spruce Biosciences, Neurocrine Biosciences, and Diurnal Ltd.
References
Key articles
White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev. 2000 Jun;21:245-91.Full text Abstract
Merke DP, Auchus RJ. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med. 2020 Sep 24;383(13):1248-61. Abstract
Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, et al. Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management. Endocr Rev. 2022 Jan 12;43(1):91-159.Full text Abstract
Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018 Nov 1;103(11):4043-88.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available here.
Use of this content is subject to our disclaimer